http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2596729-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6b4f60ab8b21d005f186ebf47dc3576 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-007 |
| filingDate | 2015-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1949d561c08f3ab7fefc105e7c16f64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0aa7f08e476ac8f8385579b03aedefd1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8956e6c7bd98361d7745efc9ba984c1a |
| publicationDate | 2016-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2596729-C1 |
| titleOfInvention | Determination of differentiated indications for choice of the method of treating keratoconus ii-iii stages |
| abstract | FIELD: medicine. n SUBSTANCE: invention refers to medicine, more specifically to ophthalmology, and can be used for pathogeneticaly grounded treatment of keratoconus stage II and III by Amsler classification. Conduct preoperative research, determination of clinical course of disease and parameters of the corneal surface. At the progressing keratoconus at patients with the minimum corneal thickness less than 400 mcm, average values of keratometry (Kav) more 55.0 D, maximum values of keratometry (Kmax) more 60.0 D - carry out implantation of rings MyoRing in intrastromal pocket with diameter 9 mm, formed at the depth of 80 % of the corneal thickness in a combination with intrastromal corneal collagen crosslinking. At the progressive keratoconus at patients with the minimum corneal thickness more than 400 mcm, Kav less 55.0 D, Kmax less 60.0 D - carry out single or serial with every 3-6 months implantation of intrastromal segments and corneal collagen crosslinking. If the absence of progressing of keratoconus and intolerance of spectacle and contact correction make implantation of rings of MyoRing. n EFFECT: method enables to reduce risk of postoperative complications, to achieve high functional results in the postoperative period. n 1 cl, 3 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018117898-A1 |
| priorityDate | 2015-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.